Breaking Barriers: CCBs and Beta-Blockers Redefine the Landscape of Hypertension Treatment

Abstract

Background: Hypertension is a significant global health challenge, with resistant hypertension posing a formidable clinical dilemma. Combination therapy with calcium channel blockers (CCBs) and beta-blockers has emerged as a promising approach to optimize blood pressure control in these patients.

Methods: We conducted a retrospective cohort study involving 2134 subjects with resistant hypertension. Data on demographics, clinical characteristics, medication history, and outcomes were collected from electronic medical records. Subjects were categorized into two groups based on their antihypertensive regimen: Group A received CCBs and beta-blockers, while Group B received other antihypertensive agents. The primary outcome was the change in systolic and diastolic blood pressure, with secondary outcomes including blood pressure control and adverse events.

Results: Combination therapy with CCBs and beta-blockers led to significant reductions in both systolic and diastolic blood pressure compared to other antihypertensive medications. A higher proportion of subjects in Group A achieved blood pressure control targets compared to Group B. The incidence of adverse events was low and comparable between the two groups.

Conclusion: Our study provides evidence supporting the efficacy and safety of combination therapy with CCBs and beta-blockers in the management of resistant hypertension. Despite limitations inherent to the retrospective design, these findings highlight the potential benefits of this treatment approach in improving blood pressure control and reducing the risk of adverse cardiovascular outcomes.

Keywords: Hypertension, resistant hypertension, calcium channel blockers, beta-blockers, combination therapy, blood pressure control, adverse events.